Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Dalin He
Observed name:
DA-LIN HE
Institution:
First Affiliated Hospital of Xi'an Jiaotong University
Observed institutions:
First Affiliated Hospital of Xi'an Jiaotong University,
First Hospital of Xi'an,
Xi'an Jiaotong University
ORCID:
0000-0003-0460-2888
Observed ORCID:
0000-0003-0460-2888
OpenAlex ID:
A5040438796
Low dose of interferon-α improves the clinical outcomes of docetaxel in patients with castration-resistant prostate cancer: A pilot study
2013
·
YUN-FEI LI
, QIN-ZHANG WANG
, et al.
·
Oncology Letters
·
11
PDF
A phase 3 trial of SHR3680 versus bicalutamide in combination with androgen deprivation therapy (ADT) in patients with high-volume metastatic hormone-sensitive prostate cancer (mHSPC).
2022
·
Ding-Wei Ye
, Weijie Gu
, et al.
·
Journal of Clinical Oncology
·
4
Systemic Immune-Inflammation Index is a Promising Noninvasive Biomarker for Predicting the Survival of Urinary System Cancers: A Systematic Review and Meta-Analysis
2021
·
Xing Li
, Lijiang Gu
, et al.
·
Research Square
·
2
PDF
Corrigendum to ‘miR-145 inhibits invasion of bladder cancer cells by targeting PAK1’
2022
·
Bo Kou
, Yang Gao
, et al.
·
Urologic Oncology Seminars and Original Investigations
·
1
Final overall survival (OS) with talazoparib (TALA) + enzalutamide (ENZA) as an initial treatment in unselected patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in the China cohort of the phase 3 TALAPRO-2 trial.
2025
·
Xiaojie Bian
, Hao Zeng
, et al.
·
Journal of Clinical Oncology
PDF
Correction: Tumor-suppressive microRNA-218 inhibits tumor angiogenesis via targeting the mTOR component RICTOR in prostate cancer
2022
·
Bing Guan
, Kaijie Wu
, et al.
·
Oncotarget
PDF
Show more works
View as search
Works count:
6
Citation count:
18
H-index:
2
I10-index:
1
Year
Topic
Type